Securitisation volume growth slows to 8% in December quarter: Report

Securitisation volume growth slows to 8% in December quarter: Report

Crisil Ratings said that the cumulative value of deals executed in the first nine months of this fiscal stood at approximately Rs 80,000 crore.

AgenciesUpdated: Monday, January 17, 2022, 10:04 PM IST
article-image
''The uncertainty around Covid-19's third wave resulted in many deals under active negotiation remaining unexecuted towards the end of the quarter,'' the agency said. |

Securitisation volume growth slowed to around 8 per cent on year to Rs 29,000 crore for the quarter ended December 31, 2021, on higher risk aversion amid the third wave of COVID-19, says a report.

Crisil Ratings said that the cumulative value of deals executed in the first nine months of this fiscal stood at approximately Rs 80,000 crore.

''The uncertainty around Covid-19's third wave resulted in many deals under active negotiation remaining unexecuted towards the end of the quarter,'' the agency said.

Prominent investing segments such as public and private sector banks preferred the relatively more resilient mortgage asset class, the report said.

(With inputs from PTI)

RECENT STORIES

CCPA Imposes ₹5 Lakh Penalty On Drishti IAS For Publishing Misleading Advertisements Regarding...

CCPA Imposes ₹5 Lakh Penalty On Drishti IAS For Publishing Misleading Advertisements Regarding...

India Is Capable Of Absorbing Global Shocks, Stands Firm Despite Volatility: FM Nirmala Sitharaman

India Is Capable Of Absorbing Global Shocks, Stands Firm Despite Volatility: FM Nirmala Sitharaman

Gold Prices Fall ₹643, Retreating From Record High To ₹1,16,945 Per 10 Grams, Profits Booked...

Gold Prices Fall ₹643, Retreating From Record High To ₹1,16,945 Per 10 Grams, Profits Booked...

Big Change In Aadhaar Update Fees, Home Service Now ₹700, Name–Photo Change Also Costlier

Big Change In Aadhaar Update Fees, Home Service Now ₹700, Name–Photo Change Also Costlier

IPO: Pharmaceutical Company Rubicon Research Set To Raise ₹1,377.50 Crore, Will Open For...

IPO: Pharmaceutical Company Rubicon Research Set To Raise ₹1,377.50 Crore, Will Open For...